KalVista Pharmaceuticals, Inc. Employee Directory
Biotechnology ResearchMassachusetts, United States201-500 Employees
KalVista Pharmaceuticals, Inc. is a biotechnology research company focused on hereditary angioedema (HAE). It aims to address the unmet needs of people living with HAE by applying its expertise across research, development, and commercialization to improve global care. Based in Framingham, Massachusetts, the firm operates with a global team and has more than 250 employees. Its work sits within the biotechnology sector, seeking therapies to expand treatment options for HAE patients. The company pursues a portfolio of novel small molecule protease inhibitors intended to treat HAE and related conditions. In 2026, KalVista launched EKTERLY (sebetralstat) for children aged 2–11 and announced positive interim Phase 3 data from the KONFIDENT-KID trial presented at a major conference.